What it is
An investigational long-acting amylin analog under clinical development, often studied as a fixed-dose combination with semaglutide (CagriSema).
How it works
Acts as a non-selective amylin receptor agonist, reducing food intake by activating amylin and calcitonin receptors in central nervous system regions involved in satiety.
Where it's used
Under investigation for chronic weight management in clinical trials.
Regulatory status
Not FDA-approved; investigational compound.
Tracking it
Cagrilintide is injectable, so two things matter in a log: when you dosed and where. Rotating sites and writing both down prevents the classic “did I already pin the left side?” problem. with a half-life of about 6.6 days (159 h), a dose log also lets a tracker model the relative amount still in your system between doses. for titrated compounds like this one, a log that records the dose at each step is the difference between knowing your history and guessing it.
Source
Public reference
Last reviewed 2026-06-11